Loading
Latest filing published 11 Mar 2024 for Outlook Therapeutics, Inc., €24k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Jeff Evanson is a declared insider of Outlook Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). The record holds 9 filings, for trades running from 19 March 2020 to 7 March 2024.
The open-market side counts 2 purchases for €66k alongside 6 sales for €597k. Sales outweigh purchases by €531k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. In 2024 alone, the filings show 1 purchase and no sales.
Most recently, on 11 March 2024, the filings show an open-market purchase worth €24k in Outlook Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations